Composition #1: Takeda, Tadahiro., Gonda, Ryoko., Hatano, Keiichiro. Constitution of lucumin and its related glycosides from Calocarpum sapota Merrill. Chemical Pharmaceutical Bulletin, 1997, p. 697–699. .
-
-
Plant part:
Seed (as part-nature) (A066P)
-
Extraction/Preparation method:
Solvent extraction (A0BZR)
-
Additional extraction description:
MeOH
-
Substance:
Cyanogenic glycosides (RF-00004375-PAR)
-
Additional substance description:
Lucumin
-
Analytical method code:
Nuclear Magnetic Resonance (NMR) (F061A)
-
Yes/No Qualitative:
Positive/Present (POS)
-
Result type:
Qualitative Value (Binary) (BIN)
-
Internal remarks:
Lucumin
Endpoint study
#1: Sathishkumar, T., Abarna, S., Malini, M., Nithya, S., Prathishta, P., Lavanya, J. Optimal extraction process and identification of A-amylase inhibitors from Pouteria sapota. international journal of pharmacy and pharmaceutical sciences, 2011, vol. 3, no. 4, p. 124–128. .
-
Study relevance:
Human health
-
Plant part:
Seed (as part-nature) (A066P)
-
Preparation/Extraction method:
Solvent extraction (A0BZR)
-
Additional plant/substance description:
solvent unspecified, 1:20 Sol:Liq (g/ml); pH 7.5, 4000 rpm for 5 min
-
Type of toxicological test:
in vitro (CHD061TT)
-
Endpoint measured:
Enzyme inhibition (CHD067EP)
-
Concentration unit:
Percent (G138A)
-
Effect concentration:
95.8
-
Critical effect:
Digestive (TOX18A)
-
Target tissue:
digestive: Pancreas (TT024A)
-
Effect description:
pancreatic alpha-amylase inhibition
-
Effect or parameter linked to the endpoint:
enzyme inhibition (CHD032BE)
-
Internal remarks:
pancreatic alpha-amylase inhibition
